Why Biogen Stock Raced Higher In August
Biotech titan Biogen (NASDAQ: BIIB) saw its shares rise by 8.73% last month, according to data from S&P Global Market Intelligence. This healthy march northward was sparked by an encouraging clinical update for the biotech's early-stage Alzheimer's disease drug candidate, aducanumab, toward the end of the month.
Specifically, Biogen reported that the long-term extension data from aducanumab's phase 1b study supported the design of the drug's ongoing phase 3 trials for early-stage Alzheimer's and seemed to back up the so-called "amyloid hypothesis" that posits that a reduction in amyloid plaques within the brain should improve cognitive abilities in patients afflicted with this devastating neurodegenerative disorder.
Image Source: Getty Images.
Source: Fool.com
Biogen Inc. Stock
The stock is one of the favorites of our community with 52 Buy predictions and 1 Sell predictions.
With a target price of 291 € there is a positive potential of 47.57% for Biogen Inc. compared to the current price of 197.2 €.
